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Available online xxxxBackground: Transmission ofMycobacterium leprae, the pathogen causing leprosy, is still persistent. To facilitate
timely (prophylactic) treatment and reduce transmission it is vital to both early diagnose leprosy, and identify
infected individuals lacking clinical symptoms. However, leprosy-speciﬁc biomarkers are limited, particularly
for paucibacillary disease. Therefore, our objective was to identify new biomarkers for leprosy and assess their
applicability in point-of-care (POC) tests.
Methods: Using multiplex-bead-arrays, 60 host-proteins were measured in a cross-sectional approach in 24-h
whole blood assays (WBAs) collected in Bangladesh (79 patients; 54 contacts; 51 endemic controls (EC)).
Next, 17 promising biomarkers were validated in WBAs of a separate cohort (55 patients; 27 EC). Finally, in a
third cohort (36 patients; 20 EC), ﬁve candidate markers detectable in plasma were assessed for application in
POC tests.
Findings: This study identiﬁed three new biomarkers for leprosy (ApoA1, IL-1Ra, S100A12), and conﬁrmed ﬁve
previously described biomarkers (CCL4, CRP, IL-10, IP-10,αPGL-I IgM). Overnight stimulation inWBAs provided
increased speciﬁcity for leprosy andwas required for IL-10, IL-1Ra and CCL4. The remaining ﬁve biomarkerswere
directly detectable in plasma, hence suitable for rapid POC tests. Indeed, lateral ﬂow assays (LFAs) utilizing this
ﬁve-marker proﬁle detected both multi- and paucibacillary leprosy patients with variable immune responses.
Interpretation: Application of novel host-biomarker proﬁles to rapid, quantitative LFAs improves leprosy diagno-
sis and allows POC testing in low-resource settings. This platform can thus aid diagnosis and classiﬁcation of lep-
rosy and also provides a tool to detectM.leprae infection in large-scale contact screening in the ﬁeld.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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User-friendly rapid test1. Introduction
Despite decades of control programs using multidrug therapy
(MDT), leprosy still poses a public health problem in low andmiddle in-
come countries affecting the poorest, most vulnerable people in their
productive stage of life [1]. This does not only have impact on affected
individuals, but also imposes a signiﬁcant social and ﬁnancial burden
on society [2].
Key to leprosy control is the reduction of transmission ofMycobacte-
rium leprae (M.leprae), the causative agent of leprosy, to breach the
number of new cases which has stagnated around 200,000 annuallyDiseases, LUMC, PO Box 9600,
. This is an open access article under
den Eeden, R. Richardus, et a
e, https://doi.org/10.1016/j.ebfor over a decade [2]. Development of methods and tools to early diag-
nose disease and detect infection to direct (prophylactic) treatment in
leprosy healthcare programs therefore has a high priority on the leprosy
research agenda.
Current diagnosis of leprosy relies on clinical symptoms requiring
well-trained clinicians. However, due to decreased clinical expertise
for leprosy in theﬁeld [3], delayed diagnosis occurs frequentlywhich in-
creases the risk of severe disabilities.M.leprae infected individuals lack-
ing clinical symptoms who are at risk of developing leprosy disease are
even more difﬁcult to identify. A diagnostic test detecting leprosy dis-
ease as well as M.leprae infection would be a valuable tool for health
care workers.
Leprosy is a spectral disease for which the clinical outcome after
M.leprae infection is determined by host factors. The spectrum spans
from anti-inﬂammatory T helper-2 (Th2) immunity concomitant withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1:1
1:2 Research in context
1:4 Evidence before this study
1:5 The annual number of new leprosy cases has been stable for the
1:6 past decade, indicating that despite the availability of effective
1:7 multidrug treatment (MDT) transmission ofMycobacterium leprae
1:8 (M.leprae) is still ongoing.
1:9 Leprosy can lead to life-long handicaps and patients frequently ex-
1:10 perience stigma, posing a severe burden. Diagnosis of leprosy re-
1:11 lies on clinical symptoms, leaving asymptomaticM.leprae infected
1:12 individuals undetected by the currently available diagnostic
1:13 methods. As it can take up to 5–10 years before clinical symp-
1:14 toms arise, it is vital that a diagnostic tool is developed to detect
1:15 M. leprae infection during this time period.
1:16 In leprosy endemic areas there is limited access to advanced
1:17 healthcare institutes and specialized clinical expertise for leprosy
1:18 has decreased enormously. This urges for newly developed
1:19 point-of-care diagnostic tests applicable in resource-limited set-
1:20 tings. Diagnostic tests to facilitate the detection of leprosy pa-
1:21 tients at an early disease stage as well as M.leprae infected
1:22 individuals will enable timely therapeutic or prophylactic treat-
1:23 ment, respectively. Overall, this will help prevent permanent
1:24 leprosy-associated disabilities.
1:25
1:26 Added value of this study
1:27 We identified a novel five-biomarker signature using a funnel ap-
1:28 proach by extensive proteomic profiling in leprosypatients, house-
1:29 hold and endemic controls in Bangladesh. Subsequently, the five-
1:30 marker signature validated in three independent cohorts was ap-
1:31 plied to a low-complexity lateral flow format; this point-of-care
1:32 test sensitively detected not only multibacillary leprosy patients
1:33 but also paucibacillary patients and thereby outperformed previ-
1:34 ously defined signatures. AsM.leprae bacilli are difficult to detect
1:35 in paucibacillary patients as well as in most infected household
1:36 contacts, and detection requires advanced laboratory equipment,
1:37 this field-friendly host biomarker-based test is well-suited for lep-
1:38 rosy diagnostics in endemic areas covering multiple aspects of
1:39 the diverse host immune response toM.leprae.
1:40
1:41 Implications of all the available evidence
1:42 This study shows the potential of biomarker profiles to identify
1:43 M. leprae infected individuals and leprosy patients. To ensure
1:44 global application validation of this five-marker signature in differ-
1:45 ent populations is required. Early diagnosis of leprosy patients and
1:46 identification ofM.leprae infected individuals is vital to reduce the
1:47 unremitting transmission. The low complexity format of the lateral
1:48 flow strips would make large-scale contact screening field trials
1:49 feasible in low resource settings, providing a diagnostic tool that
1:50 can accurately detect leprosy patients. In this respect, the de-
1:51 scribed five-marker test can aid in decision making for the WHO
1:52 endorsed targeted prophylactic treatment in M. leprae infected
1:53 contacts with single dose rifampicin. The objective read-out of
1:54 the lateral flow strips will help guide decisions on which individ-
1:55 uals are candidates for (prophylactic) treatment and facilitate lep-
1:56 rosy diagnosis, thereby significantly improving the current
1:57 diagnostic method that relies on detection of clinical symptoms.
1:58
2 A. van Hooij et al. / EBioMedicine xxx (xxxx) xxxlarge numbers of bacteria aswell as antibodies againstM.leprae antigens
in multibacillary (MB) leprosy, to paucibacillary (PB) leprosy
characterised by strong pro-inﬂammatory, T helper-1 (Th1) as well asPlease cite this article as: A. van Hooij, S. van den Eeden, R. Richardus, et a
care tests facilitates leprosy d..., EBioMedicine, https://doi.org/10.1016/j.ebT helper 17 (Th17) immunity [4]. The pro-inﬂammatory response in
PB patients leads to bacterial control, but also to collateral damage
in the form of destruction of the body's own cells by the vigorous
T cell response, mimicking autoimmunity.
Since antibodies againstM.leprae phenolic glycolipid I (PGL\\I) indi-
cate infection and are associated with bacillary load [5] rapid diagnostic
tests detecting anti-PGL-I antibodies have been developed [5,6]. How-
ever, these are still not yet widely implemented in the ﬁeld due to lim-
ited availability. Moreover, to capture the different clinical outcomes of
M.leprae infection across the leprosy disease spectrum we have shown
that both cellular and humoralmarkers should be included in diagnostic
tests: biomarker proﬁles including cellular and/or inﬂammatory bio-
markers such as CCL4, IL-10, IP-10, CRP combinedwithM.leprae speciﬁc
anti-PGL-I antibodies, increased sensitivity for leprosy [7,8]. In this re-
spect, IL-10 discriminated disease and infection from healthy status,
whereas CCL4 was particularly informative for PB patients. On one
hand, for classiﬁcation and conﬁrmation of leprosy diagnosis 24 h incu-
bation withM. leprae antigens in WBAs represents a speciﬁc approach,
similar to the application of the Quantiferon® test for TB diagnosis [9].
On the other hand, a triage for rapid identiﬁcation of infection/disease
(e.g. in large-scale contact screening efforts) must rely on biomarkers
detectable in samples directly, without stimulation. To allow improved
diagnosis and classiﬁcation of leprosy patients aswell as detection of in-
fection by triage, we thus used a funnel approach assessing additional
host proteins for their diagnostic performance in both rapid tests and
24 h WBAs, including cytokines, chemokines and growth factors
(CCGF). First, we applied high throughput multiplex bead arrays
(WBAs) and ELISAs (WBA and plasma) of samples from leprosy pa-
tients, household contacts (HC) and endemic controls (EC) from
Bangladesh. Appropriate biomarkers were subsequently validated in
low complexity, quantitative up converting phosphor lateral ﬂow as-
says (UCP-LFAs) [7].
2. Materials and methods
2.1. Study setting
During this study the prevalence in the four districts (Nilphamari,
Rangpur, Panchagar and Thakurgaon; population 8,190,035) was 0.9
per 10,000 and the new case detection rate 1.18 per 10,000 (Rural
health program, the leprosy mission Bangladesh, yearly district activity
report 2018).
2.2. Study participants
Participants were recruited on a voluntary basis between January
2013 and 2018 in leprosy endemic areas in Bangladesh as described
previously [10]. Leprosy was diagnosed based on clinical and bacterio-
logical observations and classiﬁed as MB or PB as described by the
WHO [11]. Clinical and demographic data were collected in a database.
As a reference group healthy individuals without known contact to lep-
rosy patients in their village or at work from the same area (EC) were
assessed for the absence of clinical signs and symptoms of leprosy and
TB at intake, and after 2 and 4 years. Samples were collected from 8 vil-
lages spread randomly across the study area (2 representative villages
for each of the 4 districts).
2.3. Inclusion/exclusion criteria
Patients of the Rural Health program and their contacts who were
willing to participate were included in the study [10]. Contacts were ei-
ther living in the samehouse (householdmembers) or in a house on the
same compound, sharing the same kitchen or direct neighbors (ﬁrst
neighbors). The following exclusion criteria were applied to patients:
refusal of examination of contacts, suffering from the pure neural form
of leprosy, residing only temporarily in the study area, new patientsl., Application of new host biomarker proﬁles in quantitative point-of-
iom.2019.08.009
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from a patient already included in the study or ﬁrst and second degree
relatives of a patient already included in the study. Contacts who re-
fused informed consent were also excluded, as well as anywoman indi-
cating to be pregnant, any person on TB or leprosy treatment, children
below 5 years of age, contacts known to suffer from liver disease or
jaundice, residing temporarily in the area, suffering from leprosy at
the initial survey (these patients were referred to the clinic for leprosy
treatment) and contacts who were already enrolled in the contact
group of another patient. Staff of leprosy or TB clinics were excluded
as EC.
2.4. Study cohorts
Three different cohorts were tested: a discovery cohort, including
age and gender matched [7] leprosy patients (n = 79; 34 MB; 45 PB),
HC (n=54) and EC (n=51) fromBangladesh for biomarker discovery;
two validation cohorts, cohort I for biomarker validation inWBA includ-
ing leprosy patients (n=55; 27MB; 28 PB) and EC (n=27) and cohort
II for biomarker validation in plasma consisting of leprosy patients (n=
36; 21 MB; 15 PB) and EC (n= 20). For age and gender matching a 50/
50male/female ratio and a 1:1:1 ratio of three age groups (0–14, 15–29
and 30+) was aimed at [7].
2.5. Samples
For discovery cohort and validation cohort I WBA samples, 4 ml ve-
nous blood was drawn and 1 ml applied directly to a microtube pre-
coated with 10 μg M.leprae whole cell sonicate (WCS), 10 μg ML2478
and 10 μg ML0840 recombinant proteins (combined designated as
Mlep) [3] or without stimulus (Med). Pre-coating of the tubes was
done by lyophilizing the material. After 24 h incubation at 37 °C the
microtube was frozen at −20 °C, shipped to the LUMC and stored at
−80 °C until further analysis. For validation cohort II, plasma was col-
lected as described previously [12].
2.6. Ethics
This study was performed according to the Helsinki Declaration
(2008 revision) and the study protocol was approved by the National
Research Ethics Committee (Bangladesh Medical Research Council)
(Ref no. BMRC/NREC/2010–2013/1534). Participants were informed
about the study objectives, the samples and their right to refuse to
take part or withdraw from the study without consequences for their
treatment. Written informed consent was obtained before enrolment.
All patients received treatment according to national guidelines.
2.7. Multiplex bead arrays (MBA)
BCA-1 (CXCL13), CCL17, CTACK (CCL27), sCD40L, EGF, ENA-78
(CXCL5), Eotaxin (CCL11), FGF, Flt3L, Fraktalkine (CX3CL1), G-CSF,
GM-CSF, GRO, I309, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-
16, IL-17A, IL17F, IL-20, IL-21, IL-22, IL-23, IL-27, IL28A, IL-33, IP-10,
MCP-1 (CCL2), MCP-3 (CCL7), MDC (CCL22), MIP-1α (CCL3), MIP-1β
(CCL4), PDGF-AA, PDGF-AB/BB, RANTES (CCL5), SCF, SDF-1, TGF-α,
TNF-α, TNF-β, TPO, TRAIL, TSLP and VEGFweremeasured in the discov-
ery cohort using the Milliplex magnetic bead kit (Merck, USA) as de-
scribed previously [13].
2.8. ELISAs
Validation cohort I was assessed by ELISA for ApoA1, CCL4, CFH, CRP,
CCL27, CXCL9, IL-1Ra, IL-19, IL-32, MMP9, PDGF-BB, PTX3, S100A12,
SAA1 (R&D systems, Minneapolis, USA), IP-10 and IL-10 (Diaclone Re-
search, Besancon, France) and TTR (Abcam, Cambridge, UK). To detectPlease cite this article as: A. van Hooij, S. van den Eeden, R. Richardus, et a
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Validation cohort II was assessed by ELISA for anti-PGL-I IgM, ApoA1,
CCL4, CRP, IL-1Ra, IP-10 and S100A12.
2.9. Lateral ﬂow assays (LFA)
LFAs for IP-10, CRP and αPGL-I IgM strips were produced as de-
scribed earlier [3]. ApoA1 and S100A12 strips were produced similarly
with 200 ng goat-anti-S100A12 pAb (AF1052; R&D systems,Minneapo-
lis, USA) and Goat-anti-ApoA1 pAb (AF3664; R&D systems, Minneapo-
lis, USA) on the test lines. The respective ﬂow control lines comprised
100 ng Goat-anti-Rabbit or Rabbit-anti-Goat antibody. Conjugates of
UCP particles were applied to the sample/conjugate pad at a density of
200 ng per 4 mm. UCP conjugates were prepared according to a previ-
ously described protocol [14] with Rabbit-anti-ApoA1 (Clone # 2083A;
R&D systems, Minneapolis, USA) or goat-anti-S100A12 pAb (AF1052;
R&D systems, Minneapolis, USA) at a concentration of 50 μg antibody
per mg UCP.
10μl, 1μl, 0.1μl and 0,01 μl plasma was diluted in high salt lateral
ﬂow (HSLF) buffer (100mM HEPES pH 7.5, 270mM NaCl, 1% (w/v)
BSA, 0.5% (v/v) Tween-20). 50 ul of diluted sample was added tomicro-
titer plate wells before target-speciﬁc LF stripswere placed in the corre-
sponding wells. Immunochromatography was allowed to continue for
at least 30min until dry.
2.10. Statistical analysis
Statistical analysis was performed using GraphPad Prism version 7
(GraphPad Software, San Diego,CA, USA; http://www.graphpad.com),
SPSS Statistics 24 (http://www.spss.com.hk) and R Version 3.3.0 (R, Vi-
enna, Austria; http://www.R-project.org).
Hierarchical clustering of the CCGF based on absolute correlation dif-
ference and average linkage was performed using the global test [15].
Log2 fold changes were calculated for MB, PB and HC compared to EC.
Volcano plots were computed using R, by plotting the log2 fold change
against the -log10 (p-value) of each marker (p-values calculated by
global test). Radar plots showing the log2 fold change were generated
using Excel 2016. Receiver operating characteristic (ROC) curves were
computed in Graphpad Prism and the respective area under the curve
(AUC) was calculated. Cut-offs were determined by calculating the
Youden's index [16]. To determine the optimal classiﬁcation method
three approaches (logistic regression, random forest classiﬁcation and
classiﬁcation tree) were computed using Orange data mining version
3.3.9 [17], comparing the AUC after 10-fold stratiﬁed cross-validation
for each method.
3. Results
To obtain new biomarkers for leprosy with high potential for user-
friendly POC applications, we applied a funnel approach using discovery
and validation cohorts (Fig. 1). First, in a discovery cohort of MB (n =
34) and PB (n= 45) patients, HC (n= 54) and EC (n= 51), 60 CCGFs
were measured in WBA supernatant using high throughput multiplex
bead arrays (Fig. 2; Supplementary Table S1–4): in 24 h whole blood
samples without stimulus IL-1Ra, CCL27 and CCL4 identiﬁed both MB
and PB patients. IL-6, IL-10 and IP-10 levels were signiﬁcantly different
from EC in MB patients only, whereas CCL22, PDGF-AA and PDGF-BB
identiﬁed PB patients (Fig. 2A, left column). In samples stimulated
withM. lepraeWCS IL-10 and GCSF levels were higher in both leprosy
patients and their contacts. Elevated levels of IP-10 were observed in
both MB and PB patients, whereas PDGF-BB, CCL4 and CCL27 levels
were signiﬁcantly higher for MB patients and IL-1Ra and PDGF-AA for
PB patients in response to WCS (Fig. 2A, middle column). In response
to 2M.leprae speciﬁc proteins (Mlep) CCL27 was identiﬁed as a marker
for both types of leprosy disease, IP-10 and BCA-1 for MB leprosy only
(Fig. 2A, right column). Thus, in this discovery cohort IP-10, IL-1Ra,l., Application of new host biomarker proﬁles in quantitative point-of-
iom.2019.08.009
Fig. 1. Funnel approach workﬂow. Three different cohorts including samples originating from Bangladesh (multibacillary (MB) and paucibacillary (PB) leprosy patients, household con-
tacts (HC), healthy endemic controls (EC)) were used. Bothwhole blood assays (WBA) samples (orange; unstimulated and stimulatedwithM. lepraewhole cell sonicate orM. leprae spe-
ciﬁc proteins (ML0840, ML2478)) and plasma samples (purple) were analyzed using multiplex bead assays (MBA), ELISA or up-converting phosphor lateral ﬂow assays (UCP-LFA). The
markers tested in each step are displayed in the right column. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
4 A. van Hooij et al. / EBioMedicine xxx (xxxx) xxxCCL4, CCL27 and PDGF-BB enabled the distinction of leprosy patients
from EC irrespective of leprosy classiﬁcation (Fig. 2B) and were used
for further evaluation by ELISAs in validation cohort I consisting of
27 MB patients, 28 PB patients and 27 EC. The WCS-induced levels of
IL-10 and GCSF, discriminating both patients and HC from EC signiﬁ-
cantly, correlated in the discovery cohort. Therefore, only IL-10 was in-
cluded as a marker for infection as these data conﬁrm previous reports
on IL-10 as an infection marker [7]. Additionally, 11 markers with po-
tential for diagnosis of mycobacterial diseases in earlier reports
[8,18–22] (not available in themultiplex bead assay)were also included
(Fig. 1; Supplementary Table S1). AUCswere calculated to assess the po-
tential of the markers tested to discriminate the test groups from EC,
demonstrating signiﬁcance for S100A12, CRP, ApoA1, IL-10 in response
toM.leprae speciﬁc proteins and CCL4 in response toM. lepraeWCS for
both leprosy types. Furthermore, MB patients could be discriminated
from EC based onαPGL-I IgM and IP-10 aswell, whereas for PB patients
this was feasible based on IL-10WCS, CCL4Med/CCL4Mlep and IL-1Ra
(Fig. 3A). Thus, this validation cohort conﬁrmed diagnostic potential
for leprosy of 8 markers.
Fingerstick blood (FSB) is an easy to use sample, requiring no phle-
botomist or overnight stimulation, making it suitable for rapid testing
using ﬁeld friendly LFAs. As a proxy for FSB [3] we here tested plasma
samples from Bangladeshi leprosy patients and EC (validation cohort
II) for the seven markers that were signiﬁcantly different in
unstimulated WBA samples (Fig. 3A). Since stimulation is required for
detection of IL-10 we did not further include this marker for analysisPlease cite this article as: A. van Hooij, S. van den Eeden, R. Richardus, et a
care tests facilitates leprosy d..., EBioMedicine, https://doi.org/10.1016/j.ebof plasma samples. Without antigen stimulation, anti-PGL-I IgM anti-
bodies, IP-10, CRP and S100A12 remained valuable markers in plasma
for MB patients and ApoA1 for both MB and PB (Fig. 3B), whereas IL-
1Ra and CCL4 levels could not be detected in these plasma samples.
To assess the potential of the ﬁve-marker plasma signature for POC/
ﬁeld applications, quantitative UCP-LFAs speciﬁc for ApoA1, CRP, IP-10,
αPGL-IgM and S100A12 were tested in validation cohort II. Data ob-
tained by the UCP-LFAs are in line with the ELISA data for plasma sam-
ples, with ApoA1 being the most optimal marker to discriminate PB
patients from EC, whereas the other four markers are elevated espe-
cially in MB patients, but also discriminate some PB patients from EC
(Fig. 4). To optimally identify leprosy across the disease spectrum, cut-
offs were determined comparing patients irrespective of leprosy type
to EC (Supplementary Table S5). Based on the cut-off values, the num-
ber of positive tests was determined per individual resulting in a ﬁve-
marker signature. A sum of positive test results is a practical way to
apply biomarker signatures in the ﬁeld. This signature (AUC: 0.93, p b
0,0001) identiﬁed 86% of the leprosy patients, with a speciﬁcity of 90%
(cut-off N2 tests positive). Moreover, in contrast to single markers, the
ﬁve-marker signature showed similar AUCs for MB (AUC:0,94) and PB
(AUC:0,91) patients (Fig. 4B).
Additionally, three different classiﬁcation methods (logistic regres-
sion, classiﬁcation tree and random forest classiﬁcation) were applied
to the two validation cohorts to assess the performance of the POC
ﬁve-marker signature. In general, ten-fold stratiﬁed cross-validation
showed the most optimal AUC and classiﬁcation accuracy for thel., Application of new host biomarker proﬁles in quantitative point-of-
iom.2019.08.009
Fig. 2. Production of cytokines, chemokines and growth factors (CCGFs) in leprosy patients and household contacts compared to endemic controls. 60 CCGFswere detected inwhole blood
assay (WBA) supernatant ofmultibacillary (MB) and paucibacillary (PB) leprosy patients, household contacts (HC) and endemic controls (EC). (a) Volcano plots show the log2 fold change
compared to EC (x-axis) and the -log10 (p-value) (y-axis) in unstimulatedWBA supernatant (Medium; left column), in response toM.lepraewhole cell sonicate (WCS; middle column)
and two speciﬁcM.lepraeproteins (Mlep;ML0840,ML2478; right column). Themarkers in either of the three groupswith both a log2 fold change of 1 (−1) and a p-value b0,05 ormarkers
with a p-value b0,001 are indicated (P-value b0,05 = red dot, log2 fold change of 1(−1) = orange dot, P-value b0,05 & log2 fold change of 1(−1) = green dot). (b) Summary of the
markers indicated in the volcano plots per stimulus (Medium = left, WCS = middle and Mlep = right). Radar plots show the log2 FC of the markers indicated in the volcano plots for
MB (orange), PB (blue) and HC (green) compared to the levels in EC. Dotted lines indicated a log2 FC of 1. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
5A. van Hooij et al. / EBioMedicine xxx (xxxx) xxxclassiﬁcation tree algorithm (Supplementary Table S6). The cross-
validated sensitivity and speciﬁcity of this algorithm for WBA and
plasma as assessed by ELISA was comparable to that assessed by UCP-
LFA, indicating that the signature can also be accurately detected in
POC-tests (Supplementary Fig. S1). Moreover, cross-validated signa-
tures showed only a minor decrease in sensitivity (12%)/speciﬁcity
(16%) compared to the POC signature, indicating the robustness of this
signature. The here described “funnel- approach” thus identiﬁed bio-
marker signatures, applicable to either WBAs and plasma, that sensi-
tively detect MB as well as PB leprosy patients.
4. Discussion
Tools that detect disease at an early state and identifyM.leprae infec-
tion are eminent to interrupt transmission. Previous reports showed
that the combined detection of humoral markers capturing MB leprosy
and cellular markers detecting PB, signiﬁcantly improved the detection
of leprosy patients [7,8]. However, PB patients and HC could not be dis-
tinguished as thesemarkers showed similar responses for these cellular
markers, especially in highly endemic areas [7,8]. In this study, using aPlease cite this article as: A. van Hooij, S. van den Eeden, R. Richardus, et a
care tests facilitates leprosy d..., EBioMedicine, https://doi.org/10.1016/j.ebwide array of CCGFs, ﬁve markers differentiated PB patients from HC
(Supplementary Table S2–4), whereas 18 makers were different in PB
patients compared to EC in WBA samples. These included markers pre-
viously tested in the UCP-LFA format such as CCL4, CRP and IL-10 [7,8],
as well as the newly identiﬁed markers ApoA1, IL-1Ra and S100A12.
Apolipoprotein A1 (ApoA1) is a negative acute phase protein which
is suggested to bind to stimulated T-cells thereby inhibiting contact-
mediated activation of monocytes [23] and reported to be decreased
during inﬂammation [24] and active tuberculosis [18]. Indeed, in WBA
samples both MB and PB patients showed decreased levels of anti-
inﬂammatory ApoA1. IL-1Ra (Interleukin-1 receptor antagonist) also
exerts anti-inﬂammatory functions by binding to the IL-1 receptor,
thereby inhibiting the function of the proinﬂammatory IL-1α and IL-
1β.M.leprae can induce high levels of IL-1Ra inmonocytes, and high ex-
pression of IL-1Ra in skin lesions was associated with increased suscep-
tibility to leprosy irrespective of polarity [25]. Both MB and PB patients
showed elevated levels of IL-1Ra in WBA samples, supporting the use
of IL-1Ra as a biomarker in leprosy diagnostics. S100A12 (calgranulin
C) can induce proinﬂammatory cytokines and serum levels have been
shown to correlate with disease activity in inﬂammatory disordersl., Application of new host biomarker proﬁles in quantitative point-of-
iom.2019.08.009
Fig. 3. Biomarkers validated by ELISA in whole blood assay supernatant and plasma of leprosy patients. Markers showing signiﬁcant areas under the curve (AUC) for multibacillary (MB;
orange) and/or paucibacillary (PB; blue) leprosy patients in unstimulatedwhole blood assay (WBA) supernatant (med), in response toM.lepraewhole cell sonicate (WCS) and two speciﬁc
M.leprae proteins (Mlep) (A) or plasma samples (B). Biomarkers levels were compared to those of endemic controls. Values for AUC can range from 0.5 to 1, the dotted line indicates an
AUC of 0.7. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
6 A. van Hooij et al. / EBioMedicine xxx (xxxx) xxx[26]. Interestingly, S100A12 has antimicrobial properties exerting direct
effects on both M.leprae and M.tuberculosis and was more strongly
expressed in skin lesions of PB leprosy patients [27]. Serum levels did,
however, not signiﬁcantly differ between MB and PB patients [21] in
linewith the data observed in this study. In response toM.leprae speciﬁc
proteins, S100A12 showed the optimal AUC of all the markers tested in
WBAs, both for MB and PB patients. For MB leprosy this study also
conﬁrmed the use of IP-10 as a biomarker in line with our previous
studies [7,8].
In view of point-of-care (POC) test applicability (i.e. direct analy-
sis of clinicals samples without antigen stimulation), biomarker
levels were also assessed in plasma samples as a proxy for FSB col-
lectable without venipuncture [3]. A plasma biomarker signature in-
cluding αPGL-I IgM, IP-10, S100A12, ApoA1, CRP accurately detected
leprosy patients irrespective of type with high sensitivity (86%) and
speciﬁcity (90%) in the UCP-LFAs; indicating the diagnostic value of
this signature in leprosy as it identiﬁes both patients with high and
low bacillary loads. The future detection of this signature in FSB by
rapid POC testing can be useful for screening purposes in a triage ap-
proach: a FSB-based multi-biomarker LF strip rules out individuals
who lack host biomarkers associated with leprosy, and individuals
requiring further testing are selected for overnight incubation of
whole blood with M.leprae speciﬁc antigens [7]. In the 24 h stimu-
lated WBA samples a larger selection of (stimulated) discriminatoryPlease cite this article as: A. van Hooij, S. van den Eeden, R. Richardus, et a
care tests facilitates leprosy d..., EBioMedicine, https://doi.org/10.1016/j.ebmarkers were identiﬁed, especially to detect PB patients. The levels
of biomarkers in WBAs can thus be used for multiple applications,
besides contact screening i.e. to help in classiﬁcation of leprosy pa-
tients in referral hospitals or for monitoring of the development of
complications such as leprosy reactions [12,28].
PB patients and HC show similar immune responses and often have
undetectable loads ofM.leprae bacilli. The infection status of HC is, how-
ever, largely unknown. Reports from Brazil and India indicate the pres-
ence ofM.lepraeDNA in nasal swabs and skins slit smears of HC ranging
from 8,8% to 49% [29,30] or 21%, respectively [31]. Therefore, elaborate
host immune proﬁling of HC stratiﬁed by M.leprae DNA presence in
nasal swabs or slit skin slides may aid in identifying biomarkers associ-
ated with M.leprae exposure or infection without clinical symptoms.
αPGL-I IgM levels have beenmeasured in HC in order to predict the de-
velopment of leprosy disease, but has so far proven insufﬁcient for early
detection of leprosy or onset of disease [32,33]. Longitudinalmonitoring
of the host biomarkers described in this study can provide more insight
into the predictive capacity of this biomarker signature. Moreover,
validation of this signature in different populations in leprosy endemic
areas and validation in FSB is required for large numbers of samples
before multi-biomarker testing can be implemented in leprosy
healthcare. Translation of biomarkers into clinical practice is still chal-
lenging as evidenced by the low percentage of discovered biomarkers
validated for routine clinical practice [34]. Identifying markers in threel., Application of new host biomarker proﬁles in quantitative point-of-
iom.2019.08.009
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Fig. 4. Five-marker plasma signature assessed byup-converting phosphor lateralﬂowassays (UCP-LFA). Levels ofαPGL-I IgM, IP-10, CRP, ApoA1 and S100A12weremeasuredbyUCP-LFAs
comparing 36 leprosy patients (LP, orange squares=multibacillary (MB) patients and blue dots=paucibacillary (PB) patients) to 20 endemic controls (EC=green dots). (a) Ratio values
for the 5markers testedwere calculated by dividing the relative ﬂuorescence units (RFU) from the test line (T) by the RFU from the ﬂow controls (FC). The dotted line indicates the cut-off
value for eachmarkers as calculated by the Youden's index. Values above the cut-off line are considered a positive test result, the sumof all positive tests results in the values displayed for
the ﬁve-marker signature. Cut-offs are shown in supplementary Table S5. (b) receiver operating characteristic curves (ROC) forMB and PB patients compared to EC showing all 5 markers
tested (αPGL-I IgM (red), IP-10 (purple), CRP (green), ApoA1 (blue), S100A12 (grey)) and the ﬁve-marker signature (orange).
7A. van Hooij et al. / EBioMedicine xxx (xxxx) xxxindependent cohorts using a funnel approach ensure that the strongest
biomarkers remain.
Application of biomarker signatures in rapid POC tests can not only
facilitate leprosy diagnosis and classiﬁcation but also aid decision mak-
ing on which individuals are candidate for prophylactic treatment. Con-
tacts of leprosy patients are 4 to 9 times more at risk of developing
leprosy than the general population [35]. Therefore, these individuals
are targeted for post-exposure prophylaxis. Large scale contact screen-
ing trials to selectM.leprae infected individuals for post-exposure pro-
phylaxis with single dose rifampicin (SDR) according to WHO
guidelines [28] for leprosy control will thus contribute to decrease
transmission and thereby prevent leprosy-associated irreversible
nerve damage. Moreover, the quantitative LF test data enable the as-
sessment of SDR efﬁcacy and dosage regimens in infected individuals,
as well as monitoring of treatment in leprosy patients. Importantly,
the biomarker signature identiﬁed in this study, including novelPlease cite this article as: A. van Hooij, S. van den Eeden, R. Richardus, et a
care tests facilitates leprosy d..., EBioMedicine, https://doi.org/10.1016/j.ebbiomarkers, accurately detected patients across the leprosy spectrum
and was compatible with low-complexity lateral ﬂow tests. Implemen-
tation of these host biomarker-based ﬁeld tests can thus provide the ur-
gently needed diagnostic tool for leprosy applicable in low-resource
settings.
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